boston scientific corp (BSX) Key Developments
Boston Scientific Initiates Global Study to Assess Emblem™ Subcutaneous Implantable Defibrillator (S-ICD) in Primary Prevention Patients with Low Ejection Fraction
Jun 22 15
Boston Scientific has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function (left ventricular ejection fraction = 35%). Primary prevention patients do not have a previously documented life-threatening arrhythmic event, but are at risk of sudden cardiac death and thereby indicated to receive an implantable defibrillator. This group of patients represents the high proportion of patients that are implanted with transvenous ICD (TV-ICDs) devices in the United States (U.S.) and European Union (EU). In order to further demonstrate the usefulness of the S-ICD System in this particular patient population, the UNTOUCHED study will compare outcomes during an 18-month follow-up period to objective performance criteria derived from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) study. The MADIT-RIT study evaluated shock rates in 1,500 patients implanted with TV-ICD devices and is larger randomized trials to assess shock reduction strategies for TV-ICD devices. The first patient enrolled in the global, multi-site, prospective, non-randomized study received an EMBLEM S-ICD System implant by Dr. Craig Barr, cardiologist at Russells Hall Hospital in Dudley, England. The study will enroll a minimum of 2,015 patients at up to 200 sites worldwide.
Boston Scientific Corporation Presents at Piper Jaffray Heartland Summit, Jun-23-2015
Jun 19 15
Boston Scientific Corporation Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: Michael F. Mahoney, Chief Executive Officer, President and Director.
Boston Scientific Seeks Acquisitions
Jun 9 15
Boston Scientific Corporation (NYSE:BSX) is looking for acquisition opportunities. Dan Brennan, Executive Vice President and Chief Financial Officer of Boston Scientific said, "I think with a growing top line and over the time frame that we’ve laid out through 2018-2019, I think that provides us ample opportunity for margin expansion and would allow us to continue to fund the top line, both through internal investment as well as external acquisitions and alliances as well."
Legal-Bay LLC Lawsuit Settlement Funding Reports $100 Million Verdict Against Boston Scientific Corporation in Mesh Trial
Jun 8 15
Legal-Bay LLC announced that in the first verdict against Boston Scientific since the $119 million settlement, the company was ordered to pay $100 million to a Delaware woman. The woman plaintiff claimed the vaginal mesh inserts eroded after being implanted, leaving her in constant pain and unable to have sexual intercourse. The $100 million verdict came just after Boston Scientific Corporation agreed to settle approximately 3,000 cases for $119 million. This latest verdict was the biggest yet against Boston Scientific. According to Bloomberg News, a state court jury in Delaware found that Boston Scientific's Pinnacle and Advantage Fit inserts were defectively designed and that executives in the company hid the flaws from the patient. Also according to Bloomberg, the jurors also found Boston Scientific engaged in fraud due to their failure in alerting doctors of the faulty devices' design. Legal-Bay, a law cash advance company, is ready to help women plaintiffs with various lawsuit funding services if they have a lawyer already. This includes providing up to a $50,000 cash advance on pre-settled cases and up to $250,000 on settled cases or cases that have won large mesh jury verdicts and now are a verdict on appeal or judgment on appeal case. Verdict on appeal cases take time to resolve through the courts and Legal-Bay's verdict on appeal programs are prudent for plaintiffs to take advantage of in case of a reversal of fortune.
Boston Scientific Launches Precision Novi™ Spinal Cord Stimulator System in Europe
Jun 4 15
Boston Scientific announced the European launch of the Precision Novi™ Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available. The enhanced shape of the Precision Novi implant is designed to provide a new level of comfort to patients with pain treated using primary cell therapy. Precision Novi is powered by Illumina 3D™ Software that enables physicians to target pain precisely with point-and-click simplicity. Chronic pain can have a devastating impact on quality of life for many patients. Spinal cord stimulators alleviate pain by stimulating the nerve fibers in the spinal cord to reduce pain signals. While primary cell (also referred to as non-rechargeable) devices are typically larger due to limitations in technology and battery size, the Precision Novi System represents a significant technology advance, with the smallest high-capacity battery on the market, allowing effective pain relief to be delivered from a much smaller device. The Precision Novi System is also the only primary cell device that couples with a wireless remote, empowering patients with flexibility and control over their pain management. Unlike any other primary cell system, the Precision Novi intuitive Illumina 3D neural targeting software incorporates three-dimensional lead location, as well as the conductivity of the spinal cord and surrounding tissue. This point-and-click technology automatically calculates the optimal programming configuration to target the selected pain area. Further, unique for primary cell devices, Precision Novi is a MultiWave™ Platform capable of delivering a variety of field shapes and waveforms with or without paresthesia, including burst and higher rate frequencies.